- Home
- ANL vs LPTX Comparison
ANL vs LPTX Comparison
Compare ANL & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- LPTX
- Stock Information
- Founded
- ANL 2004
- LPTX 2011
- Country
- ANL Cayman Islands
- LPTX United States
- Employees
- ANL N/A
- LPTX N/A
- Industry
- ANL
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANL
- LPTX Health Care
- Exchange
- ANL Nasdaq
- LPTX Nasdaq
- Market Cap
- ANL 61.8M
- LPTX 11.1M
- IPO Year
- ANL 2023
- LPTX N/A
- Fundamental
- Price
- ANL $1.79
- LPTX $0.31
- Analyst Decision
- ANL Hold
- LPTX Hold
- Analyst Count
- ANL 1
- LPTX 1
- Target Price
- ANL N/A
- LPTX N/A
- AVG Volume (30 Days)
- ANL 9.3K
- LPTX 802.0K
- Earning Date
- ANL 09-26-2025
- LPTX 11-12-2025
- Dividend Yield
- ANL N/A
- LPTX N/A
- EPS Growth
- ANL N/A
- LPTX N/A
- EPS
- ANL N/A
- LPTX N/A
- Revenue
- ANL N/A
- LPTX N/A
- Revenue This Year
- ANL N/A
- LPTX N/A
- Revenue Next Year
- ANL N/A
- LPTX N/A
- P/E Ratio
- ANL N/A
- LPTX N/A
- Revenue Growth
- ANL N/A
- LPTX N/A
- 52 Week Low
- ANL $1.10
- LPTX $0.22
- 52 Week High
- ANL $3.89
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- ANL 60.57
- LPTX 54.59
- Support Level
- ANL $1.65
- LPTX $0.28
- Resistance Level
- ANL $1.91
- LPTX $0.29
- Average True Range (ATR)
- ANL 0.10
- LPTX 0.02
- MACD
- ANL 0.00
- LPTX 0.00
- Stochastic Oscillator
- ANL 58.02
- LPTX 90.14
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.